ROYALTY PHARMA PLC's ticker is RPRX and the CUSIP is G7709Q104. A total of 332 filers reported holding ROYALTY PHARMA PLC in Q1 2023. The put-call ratio across all filers is 0.47 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $17,033,039 | +54.0% | 692,270 | +76.0% | 0.03% | +57.9% |
| Q1 2024 | $11,059,292 | +59.2% | 393,284 | +44.0% | 0.02% | +35.7% |
| Q4 2023 | $6,945,133 | -12.0% | 273,120 | -6.1% | 0.01% | -12.5% |
| Q3 2023 | $7,891,959 | -13.9% | 290,787 | -10.6% | 0.02% | -11.1% |
| Q2 2023 | $9,165,958 | -12.4% | 325,311 | +3.1% | 0.02% | -18.2% |
| Q1 2023 | $10,467,918 | +72472.9% | 315,650 | -13.5% | 0.02% | -18.5% |
| Q4 2022 | $14,424 | -99.6% | 364,982 | +298.6% | 0.03% | +170.0% |
| Q3 2022 | $3,756,000 | +113.8% | 91,574 | +109.5% | 0.01% | +150.0% |
| Q2 2022 | $1,757,000 | +241.8% | 43,705 | +198.0% | 0.00% | +300.0% |
| Q1 2022 | $514,000 | +26.0% | 14,667 | +25.9% | 0.00% | 0.0% |
| Q4 2021 | $408,000 | +9.4% | 11,650 | -2.6% | 0.00% | 0.0% |
| Q3 2021 | $373,000 | -29.5% | 11,959 | -21.9% | 0.00% | 0.0% |
| Q2 2021 | $529,000 | -2.8% | 15,311 | +4.5% | 0.00% | 0.0% |
| Q1 2021 | $544,000 | – | 14,657 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SIGULER GUFF ADVISERS, LLC | 6,761,970 | $338,436,000 | 92.73% |
| Vantage Consulting Group Inc | 21,477,282 | $1,074,938,000 | 87.53% |
| Memorial Sloan Kettering Cancer Center | 3,565,887 | $178,473,000 | 75.56% |
| HARVARD MANAGEMENT CO INC | 14,690,780 | $735,274,000 | 39.88% |
| ROBERT WOOD JOHNSON FOUNDATION | 3,958,498 | $1,981,228,000 | 21.69% |
| Brown University | 381,759 | $19,107,000 | 13.82% |
| Overbrook Management Corp | 778,511 | $38,964,000 | 9.50% |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 38,714,280 | $1,937,650,000 | 4.22% |
| Lagoda Investment Management, L.P. | 96,885 | $4,849,000 | 2.61% |
| HealthCor Management, L.P. | 1,339,530 | $67,043,000 | 2.58% |